Report From the NEI/FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Diseases
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The Association for Research in Vision (ARVO), together with the Foundation Fighting Blindness (FFB), organized the National Eye Institute (NEI)–Food and Drug Administration (FDA) endpoints workshop on age-related macular degeneration (AMD) and inherited retinal diseases (IRD) on November 9, 2016. The public workshop convened basic researchers, clinicians, and regulatory authorities in an interactive forum to discuss the latest clinical findings on AMD and IRD with the goal of optimizing clinical trial design and developing trial endpoints. Specifically, the aim of the workshop was to assemble stakeholders from academic and regulatory spheres to discuss clinical data on potential primary and secondary clinical trial endpoints; patient stratification for disease monitoring, interventions, and evaluation of treatment response; and identification of future research avenues. The workshop was jointly organized by Dr. Frederick Ferris III, MD, Clinical Director at the NEI; Dr. Emily Chew, MD, Deputy Clinical Director at the NEI; Dr. Karl Csaky, MD, PhD, Managing Director and Head of Molecular Ophthalmology Laboratory at the Retina Foundation of the Southwest; Dr. Jacque L. Duncan, MD, Professor of Clinical Ophthalmology at the University of California, San Francisco; and Janet K. Cheetham, PharmD, from the FFB. The workshop format was a series of presentations followed by panel discussions, in which FDA representatives offered regulatory perspectives on potential endpoints for clinical trial design. The following key topics were discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In REFLECT, all eye groups, including placebo eyes, showed a statistically significant and clinically relevant improvement24 in mean LogMAR BCVA at 1.5 years versus nadir, similar to the bilateral response seen in both treated and sham eyes in REVERSE and RESCUE, and to a degree not reported in natural history studies of LHON patients of corresponding age and genotype.18”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [24]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamoureux, E. L., Pallant, J. F., Pesudovs, K., Hassell, J. B., & Keeffe, J. E. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0220 · Cited by 227 · cited 1×
“Dagnelie discussed a relatively modern mixed PRO, namely, the IVI questionnaire.(14) The content of this questionnaire has been validated by expert panel and focus groups, and it includes three domains: mobility and independence, emotional well-being, and reading and accessing information.”
BackgroundSchmitz-Valckenberg, S., Brinkmann, C. K., Alten, F., Herrmann, P., Stratmann, N. K., Göbel, A. P., Fleckenstein, M., Diller, M., Jaffe, G. J., & Holz, F. G. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-7457 · Cited by 201 · cited 1×
“Holz described semiautomated image processing software to detect and quantify such lesions.(1) Dr.”
MethodYehoshua, Z., Wang, F., Rosenfeld, P. J., Penha, F. M., Feuer, W. J., & Gregori, G. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.05.008 · Cited by 190
Visual acuity as an outcome measure in clinical trials of retinal diseases
Beck, R. W., Maguire, M. G., Bressler, N. M., Glassman, A. R., Lindblad, A. S., & Ferris, F. L. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.06.047 · Cited by 188 · cited 1×
“percentage of success or failure between different treatment groups based on a specific number of lines on the scale.(8) Using mean changes requires smaller sample sizes in trials, increases precision, and helps avoid issues of misclassification around a”
BackgroundSelf-citationAbdelfattah, N. S., Zhang, H., Boyer, D. S., Rosenfeld, P. J., Feuer, W. J., Gregori, G., & Sadda, S. R. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-18572 · Cited by 167
Psychometric Properties of the Veterans Affairs Low-Vision Visual Functioning Questionnaire
Stelmack, J. A., Szlyk, J. P., Stelmack, T. R., Demers-Turco, P., Williams, R. T., Moran, D., & Massof, R. W. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0208 · Cited by 141 · cited 2×
“Dagnelie described a relatively modern Visual Function Questionnaire (VFQ) instrument, namely, the Veterans Administration Low Vision VFQ.(15) Dr.”
MethodRatnam, K., Carroll, J., Porco, T. C., Duncan, J. L., & Roorda, A. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-12557 · Cited by 109 · cited 1×
“Until approximately 50% of the cones were lost, visual acuity appeared to be relatively normal, decreasing below 20/25 after that threshold.(7) These findings suggest that combining AOSLO with other techniques such as SD-OCT, microperimetry, and visual acuity could increase the sensitivity of each technique for imagin…”
BackgroundSelf-citationA short-duration dark adaptation protocol for assessment of age-related maculopathy
Jackson, G. R., & Edwards, J. G. (2008) · Journal of Ocular Biology, Diseases, and Informatics · doi:10.1007/s12177-008-9002-6 · Cited by 108 · cited 1×
“Catherine Cukras discussed details of a study on dark adaptation in patients with various stages of AMD using a prototype of the AdaptDx device, which delivers an 80% focal bleach to a circular test spot on the retina located at 58 on the inferior visual meridian.(9) The study revealed that dark adaptation time tended…”
MethodLow-Luminance Visual Acuity and Microperimetry in Age-Related Macular Degeneration
Wu, Z., Ayton, L. N., Guymer, R. H., & Luu, C. D. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.02.005 · Cited by 106 · cited 1×
“3 letters in one study.(10) Independent analysis by different groups suggests that LLD measurements are reproducible and precise, as indicated by test–retest variability.”
BackgroundEye Tracking in the Wild: the Good, the Bad and the Ugly
Lappi, O. (2015) · Journal of Eye Movement Research · doi:10.16910/jemr.8.5.1 · Cited by 90 · cited 1×
“For example, stimuli in naturalistic tests are often rich and complex and include unlimited fields of view; tasks are often learned well before the experiment and embedded within natural behavior; and the behaviors entail unrestricted head and body movements and complex sequential actions.(13) Dr.”
Background
Cited by
Items 101–200 of 236
Vujosevic, S., Loewenstein, A., O’Toole, L., Schmidt-Erfurth, U. M., Zur, D., & Chakravarthy, U. (2024) · British Journal of Ophthalmology · doi:10.1136/bjo-2023-324246 · Cited by 16
“25 Until now, the most optimal test appears to be microperimetry which allows an assessment of RS at specific regions of the retina and reflects the loss of retinal tissue arising from the expansion of GA lesions.”
BackgroundInfluentialInferred retinal sensitivity in recessive Stargardt disease using machine learning
Müller, P. L., Odainic, A., Treis, T., Herrmann, P., Tufail, A., Holz, F. G., & Pfau, M. (2021) · Scientific Reports · doi:10.1038/s41598-020-80766-4 · Cited by 15
Corradetti, G., Byon, I. S., Corvi, F., Cozzi, M., Staurenghi, G., & Sadda, S. R. (2021) · Eye · doi:10.1038/s41433-021-01670-3 · Cited by 16
Inherited Retinal Disorders: Using Evidence as a Driver for Implementation
Sergouniotis, P. I. (2019) · Ophthalmologica · doi:10.1159/000500574 · Cited by 16
Test–retest repeatability of the pattern electroretinogram and flicker electroretinogram
Resende, A., Sanvicente, C., Eshraghi, H., García, A., Pickel, K., Zhang, Q., Waisbourd, M., & Katz, L. J. (2019) · Documenta Ophthalmologica · doi:10.1007/s10633-019-09707-5 · Cited by 15
Wu, Z., & Guymer, R. H. (2020) · Ophthalmologica · doi:10.1159/000510887 · Cited by 15
The Importance of Natural History Studies in Inherited Retinal Diseases
Ayala, A. R., Cheetham, J. K., Durham, T. A., & Maguire, M. G. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041297 · Cited by 15
Self-citationWu, Z., Sadda, S. R., Ach, T., Blodi, B. A., Bottoni, F. G., Chakravarthy, U., Chew, E. Y., Curcio, C. A., Ferris, F. L., Fleckenstein, M., et al. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100777 · Cited by 14
“11,19,20”
Self-citationCoulibaly, L. M., Birner, K., Zarghami, A., Gumpinger, M., Schürer‐Waldheim, S., Fuchs, P., Bogunović, H., Schmidt-Erfurth, U. M., & Reiter, G. S. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.11.005 · Cited by 14
Berlin, A., Clark, M. E., Swain, T. A., Fischer, N. A., McGwin, G., Sloan, K. R., Owsley, C. J., & Curcio, C. A. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.10.23 · Cited by 13
Therapeutic landscape for inherited ocular diseases: current and emerging therapies
Chan, H. W., Oh, J., & Leroy, B. P. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2022-179 · Cited by 13
Choi, H., Vingopoulos, F., Razavi, P., Garcia, M., Garg, I., Rodriguez, J., Finn, M., Baldwin, G. E., Romano, F., Ding, X., et al. (2024) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20240124-01 · Cited by 13
Retinal light sensitivity as outcome measure in recessive Stargardt disease
Pfau, M., Holz, F. G., & Müller, P. L. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316201 · Cited by 13
Cheloni, R., Clough, N., Jackson, D. J., & Moosajee, M. (2023) · Eye · doi:10.1038/s41433-023-02791-7 · Cited by 12
“Corneal crystals were present in 33% of patients ( n = 9).”
Safai, A., Froines, C. P., Slater, R., Linderman, R. E., Bogost, J., Pacheco, C., Voland, R. P., Pak, J. W., Tiwari, P., Channa, R., et al. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.8.42 · Cited by 12
Terheyden, J. H., Schmitz-Valckenberg, S., Crabb, D. P., Dunbar, H., Luhmann, U. F. O., Behning, C., Schmid, M. C., da Silva, R. M., Cunha-Vaz, J. G., Tufail, A., et al. (2020) · Ophthalmologica · doi:10.1159/000513591 · Cited by 12
Saeed, A., Guymer, R. H., Hadoux, X., Jannaud, M., Dang, D., Hodgson, L., Glover, E. K., Gee, E. E., van Wijngaarden, P., & Wu, Z. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100763 · Cited by 11
“13,14 Although the US Food and Drug Administration has expressed an acceptance of GA growth alone as an endpoint, 13,15 the US Food and Drug Administration has expressed a clear preference for visual function over anatomic outcome measures.”
Optical coherence tomography: when a picture is worth a million words
Tzaridis, S., & Friedlander, M. (2023) · Journal of Clinical Investigation · doi:10.1172/jci174951 · Cited by 12
Yaghy, A., Lee, A., Keane, P. A., Keenan, T. D. L., Mendonça, L. S. M., Lee, C. S., Cairns, A. M., Carroll, J., Chen, H., Clark, J., et al. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109092 · Cited by 12
Investigating Biomarkers for USH2A Retinopathy Using Multimodal Retinal Imaging
Gill, J. S., Theofylaktopoulos, V., Mitsios, A., Houston, S., Hagag, A. M., Dubis, A. M., & Moosajee, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084198 · Cited by 11
“In keeping with this, EZ width demonstrated good functional correlation and repeatability in previous RP studies [64–66], and was recommended at the National Eye Institute–FDA endpoints workshop on IRDs [60].”
BackgroundResultInfluentialGuymer, R. H. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.03.004 · Cited by 11
Birner, K., Coulibaly, L. M., Schrittwieser, J., Steiner, I., Mohamed, H., Schürer‐Waldheim, S., Gumpinger, M., Bogunović, H., Schmidt-Erfurth, U. M., & Reiter, G. S. (2024) · Acta Ophthalmologica · doi:10.1111/aos.17434 · Cited by 10
“Retinal sensitivity assessment by MP has therefore been discussed as a valuable additional functional clinical endpoint for clinical trials in above-mentioned pathologies (Csaky et al., 2018; Iftikhar et al., 2018; Pfau et al., 2024; Schönbach et al., 2017).”
InfluentialIqbal, O., Jadoon, W., Khan, I. A., Afzal, M., & Aldhahri, A. (2025) · International Journal of Computational Intelligence Systems · doi:10.1007/s44196-025-01021-0 · Cited by 10
“Various approaches were employed for the automatic detection of these retinal diseases, but substantial amounts of work in this field have been done after 2016, focusing on handcrafted features and machine learning approaches [17].”
Microperimetry and Structural Risk Factors on OCT in Intermediate Age-Related Macular Degeneration
Thomsen, A. K., Gøttsche, L. F., Hinnerskov, J. M. V., Falk, M. K., & Sørensen, T. L. (2024) · Ophthalmology Retina · doi:10.1016/j.oret.2024.02.016 · Cited by 10
Photoreceptor assessment in age-related macular degeneration
Domalpally, A., Haas, A., Chandra, S., VanderZee, B., Dimopoulos, I. S., Keenan, T. D. L., Pak, J. W., Csaky, K. G., Blodi, B. A., & Sivaprasad, S. (2024) · Eye · doi:10.1038/s41433-024-03462-x · Cited by 9
“However, the FDA declared a clear preference for functional endpoints, such as microperimetry, contrast sensitivity, and other light sensitivity measures, over structural endpoints for drug approval [114].”
InfluentialSelf-citationInvestigating Macular Tissue Integrity Index as a Novel Biomarker in Geographic Atrophy
Erb, B. M., Botros, E., Saunders, T. F., Haas, A., Voland, R. P., Linderman, R. E., Domalpally, A., & Csaky, K. G. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100871 · Cited by 9
“7 Therefore, calls have been made to reconsider the use of GA lesion growth as a surrogate end point for visual acuity (VA) in clinical trials.”
Self-citationTaylor, L. J., Josan, A. S., STRATTON, I. M., Jolly, J. K., & MacLaren, R. E. (2023) · BMC Ophthalmology · doi:10.1186/s12886-023-02974-6 · Cited by 9
“However, structural endpoints require evidence of strong correlations with functional biomarkers to be accepted as clinical trial endpoints [7, 13].”
BackgroundAgrón, E., Domalpally, A., Cukras, C. A., Chew, E. Y., & Keenan, T. D. L. (2023) · Ophthalmology · doi:10.1016/j.ophtha.2023.09.013 · Cited by 9
Self-citationA Natural History Study of RP2-Related Retinopathy
Cheloni, R., Jackson, D. J., & Moosajee, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236877 · Cited by 9
Zhao, Y., Lesmes, L. A., Dörr, M., Bex, P. J., & Lu, Z. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.1.1 · Cited by 9
Sabeti, F., Lane, J., Rohan, E. M. F., Essex, R. W., McKone, E., & Maddess, T. (2021) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-021-05296-9 · Cited by 9
Deep phenotyping of PROM1-associated retinal degeneration
Schließleder, G., Kalitzeos, A. A., Kasilian, M. L., Singh, N., Wang, Z., Hu, Z. J., Großpötzl, M., Sadda, S., Wedrich, A., Michaelides, M., et al. (2023) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-322036 · Cited by 9
Versek, C., Banijamali, S. M. A., Bex, P. J., Lashkari, K., Kamarthi, S. V., & Sridhar, S. (2021) · Eye and Brain · doi:10.2147/eb.s295745 · Cited by 9
“This novel technology could aid in early diagnosis of AMD.”
MethodInfluentialFunctional vision tests as clinical trial outcome measures in ophthalmology: a scoping review
Raji, S., Thirunavukarasu, A. J., Taylor, L. J., & MacLaren, R. E. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-097970 · Cited by 8
“In 2014, the Functional Low-Vision Observer Rated Assessment was developed as an untimed, home-based test for ultra-low vision patients in the context of a clinical trial for the Argus II retinal”
Wu, Z., Steffen, V., Harris, W., Cukras, C. A., Ferrara, D., & Guymer, R. H. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100700 · Cited by 8
Natural History of Visual Dysfunction in ABCA4 Retinopathy and Its Genetic Correlates
Pfau, M., Huryn, L. A., Boyle, M. P., Cukras, C. A., Zein, W. M., Turriff, A. E., Ullah, E., Hufnagel, R. B., Jeffrey, B. G., & Brooks, B. P. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2023.05.014 · Cited by 8
Expert CONsensus on Visual Evaluation in Retinal disease manaGEment: the CONVERGE study
Anderson, R. S., Roark, M. W., Gilbert, R. M., & Sumodhee, D. (2024) · British Journal of Ophthalmology · doi:10.1136/bjo-2024-325310 · Cited by 8
“8 9 The realisation that even logMAR charts display high”
Egger, D., Doll, B., Gonzalez, C., Ahmadzai, P., Heger, K. A., Kreid, B., Montuoro, A., Link, J., Yamaguchi, T. C., Esmaeelpour, M., et al. (2024) · Acta Ophthalmologica · doi:10.1111/aos.17431 · Cited by 7
“This reinforces the decision of the National Eye Institute and the FDA, which have put forth PR loss as a possible anatomical trial endpoint in GA (Csaky et al., 2017).”
Mukherjee, S., Arunachalam, T., Duic, C., Abraham, M., Orndahl, C. M., Menezes, S. M., Agrón, E., Pfau, M., Silva, T. D., Bailey, C., et al. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.2.7 · Cited by 7
Self-citationProgress in Inherited Retinal Disease Drug Discovery and Development: A Foundation’s Perspective
Yerxa, B. R. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2514-2 · Cited by 7
Merle, D. A., Villanueva, V. C., Righetti, G., Jung, R., Kempf, M., Kohl, S., Wissinger, B., Kuehlewein, L., Štingl, K., & Stingl, K. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.11.12 · Cited by 6
Geographic Atrophy Multifocality in the Age-Related Eye Disease Study 2
von der Emde, L. A., Hou, J., Mukherjee, S., Vance, E., Agrón, E., Domalpally, A., & Keenan, T. D. L. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.3979 · Cited by 6
Guymer, R. H., Rosenfeld, P. J., Ehlers, J. P., Attar, M., Chen, H., Ferris, F. L., Fujimoto, J. G., Ip, M. S., Pfau, M., Saßmannshausen, M., et al. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110340 · Cited by 6
Self-citationTargeted Defect-Mapping Microperimetry in Geographic Atrophy
Saeed, A., Guymer, R. H., Hadoux, X., Jannaud, M., Dang, D., Hodgson, L., Glover, E. K., Gee, E. E., van Wijngaarden, P., & Wu, Z. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100856 · Cited by 6
Terheyden, J. H., Behning, C., Lüning, A., Wintergerst, L., Basile, P. G., Tavares, D., Melício, B. A., Leal, S., Weissgerber, G., Luhmann, U. F. O., et al. (2021) · BMC Medical Research Methodology · doi:10.1186/s12874-021-01243-8 · Cited by 6
“Early stages of AMD progress slowly at an estimated rate of 5–20 per 100 person-years to late AMD [10] and frequently cause no or only little symptoms [11, 12].”
BackgroundAnders, P., Traber, G. L., Pfau, M., Riedl, S., Hagag, A. M., Zuche, H. C., Mai, J., Kaye, R., Bogunović, H., Fritsche, L. G., et al. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.8.21 · Cited by 6
Waizel, M. D. V., Traber, G. L., Maloca, P. M., Zinkernagel, M. S., Schmidt-Erfurth, U. M., Rubin, G. S., Roska, B., Otto, T. P., Weleber, R. G., & Scholl, H. P. N. (2019) · Ophthalmic Research · doi:10.1159/000501887 · Cited by 6
Reading Performance in Blue Cone Monochromacy: Defining an Outcome Measure for a Clinical Trial
Semenov, E. P., Sheplock, R., Román, A. J., McGuigan, D. B., Świder, M., Cideciyan, A. V., & Jacobson, S. G. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.13.13 · Cited by 6
Colombo, L., Bonetti, G., Maltese, P. E., Iarossi, G., Ziccardi, L., Fogagnolo, P., RUVO, V. D., Murro, V., Giorgio, D., Falsini, B., et al. (2024) · Ophthalmic Research · doi:10.1159/000538746 · Cited by 6
Alcohol Consumption and Risk of Age-Related Macular Degeneration and Geographic Atrophy Progression
Duic, C., Vance, E., Agrón, E., & Keenan, T. D. L. (2024) · Ophthalmology Retina · doi:10.1016/j.oret.2024.11.006 · Cited by 5
Birner, K., Mai, J., Boryshchuk, D., Frommlet, F., Enzendorfer, M. L., Schürer‐Waldheim, S., Gumpinger, M., Vogl, W., Leingang, O., Sacu, S., et al. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.1.22 · Cited by 5
Künzel, S. E., Kabiri, P., Bonsen, L. Z., Frentzel, D. P., Böker, A., Joussen, A. M., & Zeitz, O. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154359 · Cited by 5
“Both the FDA and the European Medicines Agency (EMA) advocate for the use of PROMs as complementary endpoints in clinical research [10–12].”
BackgroundOptical Assessment of Photoreceptor Function Over the Macula
Ni, S., Khan, S., Villar, A. J., Pennesi, M. E., Huang, D., Jian, Y., & Chen, S. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.8.41 · Cited by 5
Traber, G. L., Waizel, M. D. V., Maloca, P. M., Schmidt-Erfurth, U. M., Rubin, G. S., Roska, B., Cordeiro, M. F., Otto, T. P., Weleber, R. G., Lesmes, L. A., et al. (2020) · Ophthalmic Research · doi:10.1159/000504892 · Cited by 5
Andrews, C. D., Sheldon, A. A., Bridge, H., Downes, S. M., MacLaren, R. E., & Jolly, J. K. (2022) · Clinical ophthalmology · doi:10.2147/opth.s352004 · Cited by 5
“Functional outcomes are preferred to structural measures and the loss of peripheral visual field has been highlighted as a key component for both safety and effectivity monitoring.(4)”
BackgroundThe Natural History of CNGB1-Related Retinopathy: A Longitudinal Phenotypic Analysis
Jackson, D. J., Dubis, A. M., & Moosajee, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126785 · Cited by 5
“This is in line with a previous FDA assessment of age-related macular degeneration (AMD), whereby considerable variability has been previously shown in metrics such as visual acuity, retinal thickness, and visual fields, whereas EZ length and hyperAF ring area may be more useful in measuring photoreceptor degeneration…”
ResultKong, X., Ibukun, F. A., Khan, M. J., Hafiz, G., Wehling, D., Dreger, K. A., Singh, M. S., Birch, D., Jaffe, G. J., Naufal, F., et al. (2025) · medRxiv · doi:10.1101/2025.11.05.25339486 · Cited by 5
Self-citationParimi, V., Elsner, A. E., Burns, S. A., & Gast, T. J. (2025) · Biomedical Optics Express · doi:10.1364/boe.559475 · Cited by 4
“The FDA recommends use of VA as the primary outcome measure for evaluation of the treatment efficacy of therapeutics for retinal diseases [34].”
Großpötzl, M., Riedl, R., Schließleder, G., Hu, Z. J., Michaelides, M., Sadda, S. R., Birch, D. G., Issa, P. C., Wedrich, A., Seidel, G., et al. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2023.11.010 · Cited by 15
Terheyden, J. H., Dunbar, H., Schmitz-Valckenberg, S., Behning, C., Martinho, C., Luhmann, U. F. O., Saßmannshausen, M., Lüning, A., Miliu, A., Aires, I. D., et al. (2025) · Eye · doi:10.1038/s41433-024-03568-2 · Cited by 4
“The study consists of a cross-sectional part and a longitudinal part [9], which was informed by regulatory recommendations on the development of endpoints [10].”
InfluentialMACUSTAR-Konsortium, Terheyden, J. H., Finger, R. P., Schmitz-Valckenberg, S., Agostini, H. T., Dahlke, C., Kuehlewein, L., Lang, G. E., Pauleikhoff, D., Wolf, A., et al. (2019) · Der Ophthalmologe · doi:10.1007/s00347-019-0907-1 · Cited by 4
Eyeing a Role for Artificial Intelligence in Clinical Trials
Singh, M. S. (2023) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2022.6542 · Cited by 4
Duncan, J. L. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.12.023 · Cited by 4
Self-citationTaylor, L. J., Josan, A. S., & MacLaren, R. E. (2025) · Ophthalmic and Physiological Optics · doi:10.1111/opo.13504 · Cited by 3
“7 Therefore, this study explores the utility and repeatability of standard VA, as well as alternative acuity measures (LLVA and the MAC) in a mixed cohort of participants with a range of inherited retinal diseases.”
Gurudas, S., Marques, I. P., Girmens, J., Lechanteur, Y. T. E., Parravano, M., Berger, L., Agostini, H. T., Barrão, S., Tsiroukis, E., Monés, J., et al. (2025) · Eye · doi:10.1038/s41433-025-03895-y · Cited by 3
“A responder definition is a ≥ 15-letter change relative to baseline [6, 7].”
Vance, E., von der Emde, L. A., Mukherjee, S., Hou, J., Domalpally, A., Chew, E. Y., Chakravarthy, U., & Keenan, T. D. L. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.09.003 · Cited by 3
Self-citationDinah, C., Esmaeelpour, M., Rachitskaya, A. V., Salvo, G. D., & Munk, M. R. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101421 · Cited by 3
Kuboi, T., Chuck, R. S. H., Pineda, R., Bhushan, R., Goswamy, A., & Olson, R. J. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.07.038 · Cited by 3
Cideciyan, A. V., Román, A. J., Warner, R. L., Sumaroka, A., Wu, V. F., Jiang, Y. Y., Świder, M., Garafalo, A. V., Viarbitskaya, I., Russell, R. C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910639 · Cited by 3
“Perimetry is a valid surrogate endpoint for clinical trials that is acceptable to regulatory agencies [33,34,47].”
BackgroundMethodRodriguez-Martinez, A. C., Tailor, V., Crossland, M. D., Higgins, B. E., Blindow, E., Dekker, T. M., Greenwood, J. A., Henderson, R., Jones, P. R., & Moosajee, M. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.12.33 · Cited by 3
Parimi, V., Elsner, A. E., Papay, J. A., Clark, C. A., Miura, M., & Gast, T. J. (2024) · Ophthalmic and Physiological Optics · doi:10.1111/opo.13422 · Cited by 3
Matteson, A., Andrews, A., Huang, D., & Chen, S. (2025) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo-d-25-00066 · Cited by 3
Jeeva-Patel, T., Lutchman, C. R., & Margolin, E. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.11.006 · Cited by 3
Color Vision in Blue Cone Monochromacy: Outcome Measures for a Clinical Trial
Mascio, A. A., Román, A. J., Cideciyan, A. V., Sheplock, R., Wu, V. F., Garafalo, A. V., Sumaroka, A., Pirkle, S., Kohl, S., Wissinger, B., et al. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.1.25 · Cited by 3
FDA’s role in expediting innovation of bioelectronic implants for vision restoration
Sandrian, M. G., Ng, E., Nguyen, T., & Eydelman, M. B. (2023) · Journal of Neural Engineering · doi:10.1088/1741-2552/acd8f1 · Cited by 4
Mulders, T. W. F., van der Zanden, L., Klevering, B. J., Hoyng, C. B., & Theelen, T. (2023) · Acta Ophthalmologica · doi:10.1111/aos.15816 · Cited by 3
Malvasi, M., Compagno, S., Segnalini, A., Malvasi, V. M., Pacella, F., Turchetti, P., & Pacella, E. (2024) · Clinical Optometry · doi:10.2147/opto.s460999 · Cited by 3
Retinal Sensitivity in Comparison to Cone Density in Choroideremia
Wynne, N., Jiang, Y. Y., Alemán, T. S., & Morgan, J. I. W. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.14.6 · Cited by 3
To BCVA, or not to BCVA, that is the question
Maddess, T., & Daria, V. R. (2017) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12984 · Cited by 3
Properties of Patient-Reported Outcome Measures in Recessive Stargardt Disease
Terheyden, J. H., Finger, R. P., Wicharz, F., Herrmann, P., Holz, F. G., Tufail, A., & Müller, P. L. (2022) · Ophthalmologica · doi:10.1159/000527093 · Cited by 2
Tang, F., Chandra, S., Grewal, M. K., Raza, S. A., Wijesingha, N. S., Faes, L., Fu, D. J., Tsai, W.-S., Lim, A., & Sivaprasad, S. (2025) · Eye · doi:10.1038/s41433-025-03931-x · Cited by 2
“Best-corrected visual acuity (BCVA) is the validated functional primary endpoint accepted by regulatory agencies in clinical trials in AMD [2].”
Enzendorfer, M. L., Mai, J., Riedl, S., Bogunović, H., Menten, M. J., Rueckert, D., Fritsche, L. G., Prevost, A. T., Sivaprasad, S., Pfau, M., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.15.54 · Cited by 2
“37 This study provides a comprehensive state-of-the-art analysis incorporating a broad range of OCT-based structural features to identify the most influential contributors to functional decline in iAMD during the earliest patho-physiological processes.”
Owsley, C. J., & Curcio, C. A. (2026) · Ophthalmic and Physiological Optics · doi:10.1007/s44402-026-00124-1 · Cited by 2
“Equally important is the lack of valid and responsive functional endpoints for evaluating hypothesised early interventions that are acceptable to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the scienti fi c community [17, 18].”
Test–Retest Reliability of the Impact of Vision Impairment–Very Low Vision Questionnaire
Fink, D. J., Terheyden, J. H., Pondorfer, S. G., Holz, F. G., & Finger, R. P. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.6.6 · Cited by 2
Vincent, A., Liang, W., Maguire, M. G., Duncan, J. L., Ayala, A. R., Bernstein, P. S., Carroll, J., Cheetham, J. K., Durham, T. A., Farsiu, S., et al. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.04.034 · Cited by 2
Self-citationMukherjee, S., Vance, E., von der Emde, L. A., Arunachalam, T., Silva, T. D., Thavikulwat, A. T., Orndahl, C. M., Nyaiburi, C., Abraham, M., Hammel, K., et al. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100879 · Cited by 2
Self-citationMorgan-Warren, P. J. (2019) · European Journal of Ophthalmology · doi:10.1177/1120672119830932 · Cited by 2
Cheloni, R., Venkatesh, A., Rodriguez-Martinez, A. C., & Moosajee, M. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.12.14 · Cited by 2
“BCVA scores of counting fingers or worse represent end-stage disease with limited utility as an outcome metric in a trial setting, 35 and were excluded from progression analysis.”
BackgroundYerxa, B. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-819291-7.00006-x · Cited by 2
Novel Therapies for Inherited Retinal Dystrophies
Kay, C. N. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237358 · Cited by 2
Using Hierarchical Bayesian Modeling to Enhance Statistical Inference on Contrast Sensitivity
Zhao, Y., Lesmes, L. A., Dörr, M., & Lu, Z. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.12.17 · Cited by 1
“32,33 Adaptive procedures have traditionally been used to measure CS independently across a predetermined set of SFs in laboratory settings.”
Teixeira, S., Franca, M., Gouveia, N. M. S., Teixeira, B., da Silva, R. M., Murta, J., & Marques, J. P. (2025) · AJO International · doi:10.1016/j.ajoint.2025.100105 · Cited by 2
Paudel, N., & Daly, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1481670 · Cited by 1
Assessing structure - Function relationships in non-neovascular age-related macular degeneration
Chew, E. Y., Cukras, C. A., Duncan, J. L., Dysli, C., He, Y., Henry, E. C., Holz, F., Moult, E. M., Owsley, C. J., Roorda, A., et al. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110349 · Cited by 1
Self-citationVisualR: A novel and scalable solution for assessing visual function using virtual reality
Sozzi, F., Groß, H., Ljubisic, B., Adams, J., Gyacsok, A., Graziano, G., Weiß, S., & Pires, N. D. (2025) · Digital Health · doi:10.1177/20552076251365039 · Cited by 1
Cinque, F., Pas, J. A. A. H., Shahabi, M., Sluijterman, L., ten Brink, S. C. A., de Breuk, A., Heesterbeek, T. J., Klaver, C. C. W., Hoyng, C. C. B., & Lechanteur, Y. T. E. (2025) · Acta Ophthalmologica · doi:10.1111/aos.70008 · Cited by 1
“Current AMD trials use best-corrected visual acuity (BCVA) as a functional endpoint (Csaky et al., 2017).”
Kim, J., & Seo, J.-M. (2025) · Biomedical Engineering Letters · doi:10.1007/s13534-025-00513-4 · Cited by 2
Oldham, E. P., Hall, R. H., Jones, G., Modi, J., Ward, S., Magee, T., Fitzgerald, K., Magana, K., Hughes, G. K., Ford, A. I., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-104705 · Cited by 1
“27”
Proposal, Derivation, and External Validation of a Novel Geographic Atrophy Outcome Measure
Hou, J., von der Emde, L. A., Mukherjee, S., Vance, E., Agrón, E., Domalpally, A., Chew, E. Y., & Keenan, T. D. L. (2026) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.6002 · Cited by 1
Self-citationDeterminants of vision-related quality of life in recessive Stargardt disease
Müller, P. L., Treis, T., Finger, R. P., Wicharz, F., Holz, F. G., Tufail, A., & Terheyden, J. H. (2026) · British Journal of Ophthalmology · doi:10.1136/bjo-2025-327303 · Cited by 1
“9 A single functional outcome measure (eg, BCVA) may only describe a specific aspect of the potential subjective therapeutic impact, whereas PROM cover various facets relevant to daily life.”
Metadata
- Authors
- Csaky, K., Ferris, F., Chew, E. Y., Nair, P., Cheetham, J. K., & Duncan, J. L.
- Affiliations
- Retina Foundation of the Southwest (US)
- National Institutes of Health (US)
- Washington, District of Columbia, United States
- Foundation Fighting Blindness (US)
- University of California, San Francisco (US)
- Corresponding author
- Duncan, Jacque L.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2017-07-21
- Volume
- 58
- Issue
- 9
- Pages
- 3456
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- PMC
- PMC5961066
- OpenAlex
- W2735396028
- Cited by
- 231
- References
- 15
- Citations by year
- 2026: 22 · 2025: 38 · 2024: 40 · 2023: 28 · 2022: 26 · 2021: 28 · 2020: 25 · 2019: 15 · 2018: 8 · 2017: 1
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- age-related macular degeneration, inherited retinal disease, clinical trial endpoints, visual function outcomes, retinal degeneration
- MeSH terms
- Clinical Trials as Topic, Humans, Macular Degeneration, Retinal Diseases, Visual Acuity, Visual Fields, Endpoint Determination, Geographic Atrophy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.